查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1778916

前列腺癌治療市場－全球產業規模、佔有率、趨勢、機會及預測（按治療、按最終用戶、按地區及競爭細分，2020-2030 年）

Prostate Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球前列腺癌治療市場價值為 134.5 億美元，預計到 2030 年將達到 212.3 億美元，預測期內的複合年成長率為 8.05%。前列腺癌治療市場正在經歷顯著成長，這得益於人們認知的提高、發病率的上升以及診斷和治療技術的進步。由於前列腺癌仍然是男性中最常見的癌症之一，因此對針對該疾病各個階段的有效治療方案的需求日益成長。市場涵蓋了各種各樣的療法，包括荷爾蒙療法、化療、免疫療法和標靶療法。其中，雄激素剝奪療法繼續發揮核心作用，而較新的標靶療法和免疫療法由於其能夠提供更個人化和有效的護理而越來越受到關注。

市場概覽
預測期 2026-2030
2024年市場規模 134.5億美元
2030年市場規模 212.3億美元
2025-2030 年複合年成長率 8.05%
成長最快的領域 醫院
最大的市場 北美洲

例如，根據美國癌症協會的資料，前列腺癌在老年男性中最為常見，約 60% 的診斷發生在 65 歲及以上的人群中，而在 40 歲以下的男性中很少見。男性首次診斷的典型年齡在 67 歲左右。這對老齡化人口的重大影響推動了對前列腺癌治療的需求。

關鍵市場促進因素

攝護腺癌發生率上升

主要市場挑戰

治療費用高昂

解決成本障礙對於擴大全球治療機會、改善醫療公平性以及確保前列腺癌治療市場的永續成長至關重要。

主要市場趨勢

精準醫療和標靶治療

目錄

第1章：服務概述

  • 市場定義
  • 市場範圍
    • 覆蓋市場
    • 考慮學習的年限
    • 主要市場區隔

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球前列腺癌治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療方法（荷爾蒙療法、化療、免疫療法、標靶治療、其他）
    • 按最終使用者（醫院、腫瘤診所、門診手術中心等）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖
    • 按治療
    • 按最終用戶

第6章：北美攝護腺癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲攝護腺癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區前列腺癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲

第9章：南美洲攝護腺癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲前列腺癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 沙烏地阿拉伯非洲

第 11 章：市場動態

  • 驅動程式
    • 攝護腺癌盛行率不斷上升。
    • 採用新型篩檢和診斷技術
    • 研發熱潮
  • 挑戰
    • 癌症治療費用高昂
    • 荷爾蒙治療的副作用

第 12 章：市場趨勢與發展

  • 產品發布
  • 併購
  • 技術進步

第 13 章：臨床試驗分析

第 14 章：全球前列腺癌治療市場：SWOT 分析

第 15 章：競爭格局

  • Johnson & Johnson Services, Inc.
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • Sanofi SA
  • Ipsen Pharma
  • Bayer AG
  • AstraZeneca Plc
  • Valeant Pharmaceuticals International, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 14698

Global Prostate Cancer Therapeutics Market was valued at USD 13.45 billion in 2024 and is expected to reach USD 21.23 billion by 2030 with a CAGR of 8.05% during the forecast period. The prostate cancer therapeutics market is experiencing significant growth, driven by rising awareness, increasing incidence rates, and advancements in diagnostic and treatment technologies. As prostate cancer remains one of the most commonly diagnosed cancers in men, there is a growing demand for effective treatment options across all stages of the disease. The market encompasses a wide range of therapies, including hormone therapy, chemotherapy, immunotherapy, and targeted therapy. Among these, androgen deprivation therapy continues to play a central role, while newer targeted treatments and immunotherapies are gaining traction due to their ability to provide more personalized and effective care.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 13.45 Billion
Market Size 2030USD 21.23 Billion
CAGR 2025-20308.05%
Fastest Growing SegmentHospitals
Largest MarketNorth America

For instance, according to data from the American Cancer Society, prostate cancer is most prevalent in older men, with around 60% of diagnoses occurring in those aged 65 and above, while it is rare in men under 40. The typical age for a man's first diagnosis is around 67. This significant impact on an aging population drives the demand for prostate cancer therapeutics.

Key Market Drivers

Rising Prevalence of Prostate Cancer

The rising prevalence of prostate cancer is a significant driver propelling the growth of the prostate cancer therapeutics market. For instance, according to the Global Cancer Observatory's GLOBOCAN 2022 report, prostate cancer ranked 4th among all cancer types, with approximately 1.47 million new cases reported in 2022. This high incidence rate significantly increases the demand for effective treatment options, driving the growth of the prostate cancer therapeutics market. Also, November is globally recognized as Prostate Cancer Awareness Month, focusing on raising awareness for prostate cancer in men. In November 2024, Europa Uomo members in Hungary and Italy contributed to this cause by launching prostate cancer testing programs as part of the "Movember" campaign. Prostate cancer has become one of the most commonly diagnosed cancers among men worldwide, with its incidence steadily increasing, particularly in aging populations. As life expectancy rises globally, the number of men at risk for prostate cancer also grows, leading to higher diagnosis rates. This trend is especially pronounced in developed countries where healthcare systems are more likely to perform regular screenings, including prostate-specific antigen (PSA) testing, resulting in earlier and more frequent detection of the disease.

The lifestyle changes such as sedentary habits, poor diet, and obesity-factors known to increase the risk of prostate cancer-are becoming more prevalent across both developed and developing nations. As awareness about the disease improves, more individuals are seeking early screening and diagnosis, which in turn increases the number of patients requiring treatment. This surge in demand places pressure on the healthcare system and pharmaceutical companies to innovate and deliver more effective, accessible, and targeted therapies.

The increasing prevalence of prostate cancer not only intensifies the need for conventional hormone and chemotherapy treatments but also creates opportunities for emerging therapies such as immunotherapy and precision medicine. Pharmaceutical firms are accelerating their research efforts to address the rising patient burden with therapies that offer better efficacy, fewer side effects, and improved survival rates. Governments and healthcare organizations are allocating more resources to prostate cancer research, awareness campaigns, and treatment access, particularly in regions where healthcare infrastructure is evolving. As a result, the growing prevalence of prostate cancer is acting as a catalyst for innovation, investment, and market expansion, making it a central force shaping the future of prostate cancer therapeutics globally.

Key Market Challenges

High Treatment Costs

High treatment costs represent a significant barrier to the growth and accessibility of the prostate cancer therapeutics market. Advanced therapies, such as targeted treatments, immunotherapies, and radioligand therapies, often come with premium pricing due to complex development processes, high research and manufacturing costs, and stringent regulatory requirements. These elevated costs can limit access to cutting-edge treatments, particularly in low- and middle-income countries where healthcare funding is constrained and out-of-pocket expenditures are common. Even in high-income regions, the financial burden on healthcare systems and patients can be substantial, often leading to disparities in care based on socioeconomic status or insurance coverage.

The long-term nature of prostate cancer treatment also contributes to rising expenses. Many patients require ongoing therapy over several years, which can accumulate into a significant financial strain. This is further complicated when patients develop resistance to first-line treatments, necessitating the use of newer, often more expensive, second- or third-line therapies. The associated costs such as diagnostics, monitoring, hospitalization, and supportive care amplify the total financial burden.

High treatment costs can also affect adherence to therapy, as some patients may discontinue or delay treatment due to affordability issues. This can result in disease progression and higher downstream healthcare expenses. From a market perspective, pricing pressures and reimbursement challenges may hinder the adoption of innovative therapies, slowing market growth and limiting the return on investment for pharmaceutical companies.

Addressing the cost barrier will be essential for expanding global access, improving equity in care, and ensuring the sustainable growth of the prostate cancer therapeutics market.

Key Market Trends

Precision Medicine and Targeted Therapies

Precision medicine and targeted therapies are playing an increasingly critical role in shaping the future of the prostate cancer therapeutics market. As the understanding of prostate cancer biology deepens, treatment strategies are shifting from a one-size-fits-all approach to more personalized interventions that are tailored to the genetic and molecular profiles of individual patients. This shift is enhancing treatment efficacy, reducing side effects, and improving patient outcomes. Targeted therapies, particularly androgen receptor signaling inhibitors and PARP inhibitors, are at the forefront of this transformation. These treatments are designed to interfere with specific biological pathways that drive cancer growth, offering greater precision than traditional hormone therapies or chemotherapy. For example, PARP inhibitors have shown significant promise in patients with BRCA1 or BRCA2 gene mutations, marking a major advancement in treating advanced or metastatic prostate cancer.

Precision medicine also supports the identification of biomarkers that help predict a patient's response to specific therapies, guiding clinicians in selecting the most effective treatment from the outset. This not only increases treatment success rates but also reduces the likelihood of adverse effects associated with ineffective therapies. The growing demand for targeted therapies has spurred increased investment in research and development, with numerous precision drugs currently in clinical trials. Regulatory bodies are responding by granting expedited approvals for breakthrough therapies, accelerating their entry into the market. As more patients and healthcare providers adopt precision medicine approaches, this trend is expected to drive innovation, improve patient stratification, and significantly expand the prostate cancer therapeutics market in the coming years.

Key Market Players

  • Johnson & Johnson Services, Inc.
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • Sanofi S.A.
  • Ipsen Pharma
  • Bayer AG
  • AstraZeneca Plc
  • Valeant Pharmaceuticals International, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

Report Scope:

In this report, the Global Prostate Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Therapeutics Market, By Treatment:

  • Hormonal Therapy
  • Immunotherapy
  • Targeted Therapy
  • Others

Prostate Cancer Therapeutics Market, By End User:

  • Hospitals
  • Specialized Clinics
  • Ambulatory Surgical Centers
  • Others

Prostate Cancer Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prostate Cancer Therapeutics Market.

Available Customizations:

Global Prostate Cancer Therapeutics Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Prostate Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
      • 5.2.1.1. Hormonal Therapy
        • 5.2.1.1.1. Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
        • 5.2.1.1.2. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
        • 5.2.1.1.3. Anti-Androgen
      • 5.2.1.2. Chemotherapy
        • 5.2.1.2.1. Taxotere
        • 5.2.1.2.2. Jevtana
      • 5.2.1.3. Immunotherapy
        • 5.2.1.3.1. Provenge
      • 5.2.1.4. Target Therapy
        • 5.2.1.4.1. Xofigo
    • 5.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By End User

6. North America Prostate Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
    • 6.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prostate Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Prostate Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Prostate Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By End User

7. Europe Prostate Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
    • 7.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Prostate Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End User
    • 7.3.2. Germany Prostate Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Prostate Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Prostate Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Prostate Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By End User

8. Asia-Pacific Prostate Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
    • 8.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Prostate Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End User
    • 8.3.2. Japan Prostate Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End User
    • 8.3.3. India Prostate Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Prostate Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Prostate Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End User

9. South America Prostate Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
    • 9.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Prostate Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Prostate Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Prostate Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By End User

10. Middle East and Africa Prostate Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other)
    • 10.2.2. By End User (Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Prostate Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Prostate Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By End User
    • 10.3.3. Saudi Africa Prostate Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Increasing Prevalence of Prostate Cancer.
    • 11.1.2. Adoption of Novel Screening and Diagnostic Technologies
    • 11.1.3. Surge in Research and Development
  • 11.2. Challenges
    • 11.2.1. High Cost of Cancer Treatment
    • 11.2.2. Side Effects of Hormonal Treatment

12. Market Trends & Developments

  • 12.1. Product Launches
  • 12.2. Mergers & Acquisitions
  • 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Prostate Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

  • 15.1. Johnson & Johnson Services, Inc.
  • 15.2. Astellas Pharma Inc.
  • 15.3. Eli Lilly and Company
  • 15.4. Sanofi S.A.
  • 15.5. Ipsen Pharma
  • 15.6. Bayer AG
  • 15.7. AstraZeneca Plc
  • 15.8. Valeant Pharmaceuticals International, Inc.
  • 15.9. Merck & Co., Inc.
  • 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer